Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-04-21

Clinical Trial Update: Erlotinib Prevention of Oral Cancer (EPOC) [Phase 3]

View source ↗

Summary

Phase 3 trial update on erlotinib for prevention of oral cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ERLOTINIB (Erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Oral Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-04-21